Profile data is unavailable for this security.
About the company
bioXXmed AG is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.
- Revenue in EUR (TTM)3.49k
- Net income in EUR-996.91k
- Incorporated2006
- Employees1.00
- LocationbioXXmed AGZiegelhaeuser Landstrasse 3HEIDELBERG 69120GermanyDEU
- Phone+49 62 216492488
- Fax+49 61 519515813
- Websitehttps://bioxxmed.ag/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MagForce AG | 351.98k | -10.57m | 179.59k | 69.00 | -- | 0.0067 | -- | 0.5102 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
| bioXXmed AG | 3.49k | -996.91k | 336.03k | 1.00 | -- | 1.05 | -- | 96.28 | -5.23 | -5.23 | 0.0176 | 1.17 | 0.006 | -- | 0.0572 | 3,490.00 | -170.22 | -39.81 | -206.00 | -40.13 | -- | -- | -28,564.76 | -25,207.92 | -- | -6.95 | 0.00 | -- | -79.94 | -37.36 | 95.24 | -- | -- | -- |
| Oxurion NV | 2.00k | 1.96m | 420.59k | 11.00 | 0.0098 | -- | 0.2075 | 210.30 | 0.6137 | 0.6137 | 0.0006 | -3.76 | 0.0004 | -- | 0.0015 | 181.82 | 41.10 | -101.52 | -- | -249.96 | -650.00 | 53.85 | 97,950.00 | -2,672.68 | -- | -- | -- | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 598.48k | 87.00 | -- | 0.0301 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | 0.1146 | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
| PCI Biotech Holding ASA | 415.84k | -1.82m | 715.16k | 7.00 | -- | 0.6442 | -- | 1.72 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Epigenomics AG | 4.00k | -2.76m | 762.95k | 3.00 | -- | -- | -- | 190.74 | -3.14 | -3.14 | 0.0046 | 0.00 | 0.0003 | -- | -- | 2,000.00 | -23.10 | -55.09 | -23.17 | -61.61 | -2,300.00 | -0.2095 | -69,025.00 | -473.65 | -- | -- | 1.00 | -- | -100.00 | -- | 24.90 | -- | -- | -- |
| GeNeuro SA | 0.00 | -14.76m | 916.64k | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Shortwave Life Sciences PLC | -4.95k | -406.20k | 998.45k | 2.00 | -- | 0.3526 | -- | -- | -0.0085 | -0.0085 | -0.0001 | 0.0454 | -0.0014 | -- | -- | -2,150.00 | -11.85 | -- | -12.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -19.39 | -- | 76.00 | -- | -- | -- |
| Paion AG | -100.00bn | -100.00bn | 998.72k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| Stayble Therapeutics AB | 0.00 | -794.80k | 1.16m | 2.00 | -- | 1.45 | -- | -- | -0.168 | -0.168 | 0.00 | 0.1314 | 0.00 | -- | -- | 0.00 | -78.98 | -78.82 | -83.99 | -92.78 | -- | -- | -- | -- | -- | -- | 0.0913 | -- | -- | -- | 47.69 | -- | -- | -- |
